



MPS PHARMAA LIMITED
(FORMERLY ADVIK LABORATORIES LIMITED)

Date: 4th February, 2023

To,
The Manager (Listing)
Bombay Stock Exchange Limited,
01st Floor, P.J. Tower
Dalal Street, Mumbai-400001

Sub: **Submission of Newspaper Publication w.r.t. Un-audited Financial Results for the quarter ended 31st December, 2022**

Ref: **Ref: BSE Scrip Code- 531686; ASE Scrip Code- 01638 (ADVIK LABO)**

Dear Sir,

Pursuant to Regulation 47 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, please find enclosed herewith a copy of newspaper publication w.r.t Un-audited Financial Results for the quarter ended 31st December, 2022, published on 4th February, 2023 in "Financial Express," English Newspaper, & "Jansatta", Hindi Newspaper, All India edition.

We hope that you will find the above in order. This is for your information and records please.

Thanking You.

For MPS Pharmaa Limited
(Formerly Advik Laboratories Limited)

POOJA CHUNI Digitally signed by POOJA CHUNI
Date: 2023.02.04 12:06:05 +05'30'

Pooja Chuni
Company Secretary

Encl: As Above

CC.:

The Manager (Listing),
Ahmedabad Stock Exchange Limited,
1st Floor, Kamdhenu Complex,
Opp. Sahajanand College
Panjara Pole, Ambawadi, Ahmedabad - 380015

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal building 19, Barakhamba Road, Connaught Place, New Delhi 110001

Phones: 011-42424884, 43571040-45, Fax: 011-43571047

Regd. Office & Factory: 138. ROZ-KaMeo Industrial Area, Sohna - 122103 (Distt.Mewat), Haryana

Phones: 0124-2362471 Email: mail@advikindia.com Website: www.advikindia.com

TATA ELXSI LIMITED

CIN : L85110KA1989PLC009968

Registered & Corporate office: Tata Elxsi Limited, ITPB Road, Whitefield, Bengaluru 560048
 Website: www.tataelxsi.com | E-mail: investors@tataelxsi.com
 Tel: +91 80 2297 9123

NOTICE OF POSTAL BALLOT - ELECTRONIC DISPATCH

Members are hereby notified that the Postal Ballot Notice dated January 25, 2023 along with the explanatory statement for adoption of the 'Tata Elxsi Limited - Performance Stock Option Plan - 2023', has been sent electronically by e-mail on February 01, 2023 to all the Members whose e-mail addresses are registered and available with the Company / Depositories as on the Cut-Off date i.e. Friday, January 20, 2023.

The Company has engaged the services of NSDL for facilitating remote e-voting to enable the Members to cast their votes electronically. The remote e-voting period shall commence on **Friday, February 03, 2023, at 9:00 a.m. (I.S.T.) and end on Saturday, March 04, 2023, at 5:00 p.m. (I.S.T.)**. The remote e-voting module shall be disabled by NSDL thereafter. Members may refer to the Postal Ballot Notice for detailed instructions on the voting procedures.

The Postal Ballot Notice is available on the Company's website www.tataelxsi.com and on the website of NSDL www.evoting.nsdl.com.

Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30.

for TATA ELXSI LIMITED
Sd/-

Place : Bengaluru
Dated : February 03, 2023

Cauveri Sriram
Company Secretary

MPS PHARMAA LIMITED (Formerly Advik Laboratories Limited)			
Regd. Off.: 138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat, Haryana-122103			
CIN: L74899HR1994PLC038300 Tele no.: 011-42424884, Fax no.: 011-43571047, Website: www.mpspharmaa.com, Email: info@mpspharmaa.com			
EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2022			
Particulars	(Rs. In Lacs)		
	For the quarter ended 31.12.2022 (Un-audited)	For the nine months ended 31.12.2022 (Un-audited)	For the quarter ended 31/12/2021 (Un-audited)
Total Income from operations			3.24
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(26.30)	(74.82)	(29.30)
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(26.30)	(74.82)	(29.30)
Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(25.91)	(73.50)	(27.48)
Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(25.48)	(72.22)	(27.38)
Equity Share Capital	1,911.14	1,911.14	1,911.14
Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of previous year)			
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)			
Basic	(0.14)	(0.38)	(0.14)
Diluted	(0.14)	(0.38)	(0.14)

Note: The above is an extract of the detailed format of Unaudited Financial Results for the Quarter & nine months ended December 31, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the aforesaid Quarterly Financial Results is available on the Stock Exchanges websites, viz., www.bseindia.com, www.aselindia.co.in and on the Company's website www.mpspharmaa.com.

For and on behalf of the Board of Directors of
MPS Pharmaa Limited
(Formerly Advik Laboratories Limited)
Sd/-
Peeyush Kumar Aggarwal
Chairman
DIN: 00090423

Place: New Delhi
Date: 03rd February, 2023

Formerly Advaita Allied Health Services Limited)
CIN: L74999MH2019PLC320039
Ready Money Mansion, Dr. Annie Besant Road,
Worli, Mumbai, Maharashtra, India, 400018
Website: www.maxindia.com

ULTS 31, 2022				
(Rs. in Crores)				
Consolidated				
Year ended 31.03.2022	Quarter ended 31.12.2022	Quarter ended 31.12.2021	Year ended 31.03.2022	
(Audited)	(Unaudited)	(Unaudited)	(Audited)	
33.86	46.15	42.83	237.44	
7.63	(4.29)	(4.92)	(14.80)	
7.63	(4.29)	(4.92)	(19.93)	
6.30	(0.76)	(5.70)	(18.04)	
6.51	(0.53)	(5.63)	(17.45)	
53.79	43.03	53.79	53.79	
881.81			583.31	
1.17	(0.24)	(1.05)	(3.35)	
1.17	(0.23)	(1.05)	(3.35)	

2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the aforesaid Quarterly Financial Results is available on the Stock Exchanges websites, viz., www.bseindia.com, www.aselindia.co.in and on the Company's website www.mpspharmaa.com.

By Order of the Board

Rajit Mehta
Managing Director
DIN : 01604819



**RP - Sanjiv Goenka
Group**

Growing Legacies

**Firstsource Solutions Limited****EXTRACT OF THE CONSOLIDATED UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022**

(Rs. in millions, except per share data and per equity data)

Sl. No.	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
		Audited	Audited	Audited	Audited	Audited	Audited
1	Total Income from Operations	15,673.72	15,376.03	14,640.31	45,836.84	43,781.65	59,217.08
2	Net Profit / (Loss) for the period/year (before Tax, Exceptional and/or Extraordinary items)	1,836.67	1,549.24	1,613.52	4,433.45	4,910.99	6,471.01
3	Net Profit / (Loss) for the period/year before tax (after Exceptional and/or Extraordinary items)	1,836.67	1,549.24	1,613.52	4,433.45	4,910.99	6,471.01
4	Net Profit / (Loss) for the period/year after tax (after Exceptional and/or Extraordinary items)	1,579.22	1,294.01	1,354.54	3,724.10	4,041.42	5,365.30

India Ltd.

Mumbai - 400021, India.
@shippingcorp

75
Azadi Ka
Amrit Mahotsav



MONTHS ENDED DECEMBER 31, 2022

(Amount in ₹ Lakhs)

CONSOLIDATED		
Quarter Ended 31.12.2022 (Unaudited)	Nine Months Ended 31.12.2022 (Unaudited)	Quarter Ended 31.12.2021 (Unaudited)
1,579.22	1,294.01	1,354.54